ヒドロキシクロロキンやコルヒチンの継続的治療はSARS-CoV-2感染を予防しない PMID:32380315

論文タイトル

Gendelman O, Amital H, Bragazzi NL, Watad A, Chodick G.

Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis

[published online ahead of print, 2020 May 4]. 

Autoimmun Rev. 2020;102566. doi:10.1016/j.autrev.2020.102566

論文→Shaperで原文を整える→DeePLに翻訳させる
この作業だけをして、翻訳を載せています。

アブストラクト(抄録)

背景

リウマチ性疾患/自己免疫疾患の患者さんの治療に一般的に使用されているヒドロキシクロロキンやコルヒチンなどの疾患修飾薬の中には、「コロナウイルス病2019」(COVID-19)の治療薬としての可能性が検討されているものもあります。しかし、これらの薬剤が予防ツールとしてどのような役割を果たすのかはまだ明らかになっていない。

方法

本研究は、2020年2月23日から2020年3月31日までの研究期間中に「重症急性呼吸器症候群コロナウイルス2型(SARS-CoV-2)」のスクリーニングを受けた全患者を含む大規模な医療用コンピュータデータベースをベースにしたレトロスペクティブ研究です。SARS-CoV-2陽性と判定された被験者と陰性と判定された被験者との間で、ヒドロキシクロロキン/コルヒチン療法の投与率を比較した。

結果

全サンプル14,520人を対象にSARS-CoV-2感染のスクリーニングが行われ、1317人が陽性となった。SARS-CoV-2感染陽性者と陰性者の間では、ヒドロキシクロロキンまたはコルヒチンの使用率に有意差は認められなかった(ヒドロキシクロロキンは0.23%対0.25%、コルヒチンは0.53%対0.48%)。

結論

これらの知見は、SARS-CoV-2感染症との戦いにおけるこれらの薬剤の保護的役割に疑問を投げかけている。

References

  1. World Health OrganizationPneumonia of unknown cause–C… – Google Scholar(2020)https://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=World+Health+Organization&title=Pneumonia+of+unknown+cause+%E2%80%94+China.#d=gs_cit&u=%2Fscholar%3Fq%3Dinfo%3AlPAb-NcXDlIJ%3Ascholar.google.com%2F%26output%3Dcite%26scirp%3D0%26hl%3DenAccessed 13 Apr 2020Google Scholar
  2. S. Appel, O. Kaidar-Person, Y.R. Lawrence, M. Ben-Ayun, T. Katzman, J. Bar, et al.The coronavirus pandemic in Israel: implications for radiation oncology departmentsIMAJ, 22 (2020), pp. 211-213View Record in ScopusGoogle Scholar
  3. Z. Wu, J.M. McGooganCharacteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and PreventionJAMA (2020), 10.1001/jama.2020.2648[Epub ahead of print]Google Scholar
  4. W. Guan, Z. Ni, Y. Hu, W. Liang, C. Ou, J. He, et al.Clinical characteristics of coronavirus disease 2019 in ChinaN Engl J Med (2020), 10.1056/NEJMoa2002032Google Scholar
  5. A.J. Rodriguez-Morales, J.A. Cardona-Ospina, E. Gutiérrez-Ocampo, R. Villamizar-Peña, Y. Holguin-Rivera, J.P. Escalera-Antezana, et al.Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysisTravel Med Infect Dis (2020), p. 101623ArticleDownload PDFGoogle Scholar
  6. J. Sun, W.-T. He, L. Wang, A. Lai, X. Ji, X. Zhai, et al.COVID-19: epidemiology, evolution, and cross-disciplinary perspectivesTrends Mol Med, 26 (5) (2020), pp. 483-495ArticleDownload PDFView Record in ScopusGoogle Scholar
  7. J. Yang, Y. Zheng, X. Gou, K. Pu, Z. Chen, Q. Guo, et al.Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysisInt J Infect Dis (2020), 10.1016/j.ijid.2020.03.017Google Scholar
  8. V. SurveillancesThe epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020China CDC Weekly, 2 (2020), pp. 113-122Google Scholar
  9. B. Li, J. Yang, F. Zhao, L. Zhi, X. Wang, L. Liu, et al.Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in ChinaClin Res Cardiol (2020), 10.1007/s00392-020-01626-9Google Scholar
  10. E. Livingston, K. BucherCoronavirus disease 2019 (COVID-19) in ItalyJAMA, 323 (2020), p. 1335, 10.1001/jama.2020.4344[Epub ahead of print]CrossRefGoogle Scholar
  11. C.M. Petrilli, S.A. Jones, J. Yang, H. Rajagopalan, L.F. O’Donnell, Y. Chernyak, et al.Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York CitymedRxiv (2020)Google Scholar
  12. C. COVID, R. TeamSevere outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–march 16, 2020MMWR Morb Mortal Wkly Rep, 69 (2020), pp. 343-346Google Scholar
  13. A. Kimball, K.M. Hatfield, M. Arons, A. James, J. Taylor, K. Spicer, et al.Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–march 28, 2020(2020)Google Scholar
  14. R.E. Jordan, P. Adab, K.K. ChengCovid-19: risk factors for severe disease and deathBMJ, 368 (2020), 10.1136/bmj.m1198Google Scholar
  15. T. LancetThe gendered dimensions of COVID-19Lancet (London, England), 395 (2020), p. 1168Google Scholar
  16. Y. ShoenfeldCorona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planningAutoimmun Rev (2020), Article 102538, 10.1016/j.autrev.2020.102538[Epub ahead of print]ArticleDownload PDFGoogle Scholar
  17. Coronavirus_med_guidelines.pdf (2020)https://www.health.gov.il/Subjects/disease/corona/Documents/coronavirus_med_guidelines.pdfAccessed 14 Apr 2020Google Scholar
  18. S. GargHospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, march 1–30, 2020MMWR Morb Mortal Wkly Rep, 69 (2020)Google Scholar
  19. Country Comparison :: Median age — The World Factbook – Central Intelligence Agencyhttps://www.cia.gov/library/publications/the-world-factbook/fields/343rank.html (2020)Accessed 19 Apr 2020Google Scholar
  20. L.B. Oestergaard, M.D. Schmiegelow, N.E. Bruun, R.L. Skov, A. Petersen, P.S. Andersen, et al.The associations between socioeconomic status and risk of Staphylococcus aureus bacteremia and subsequent endocarditis – a Danish nationwide cohort studyBMC Infect Dis, 17 (2017), p. 589Google Scholar
  21. Socioeconomic gradient in health and the COVID-19 outbreak (2020)https://www.bmj.com/content/368/bmj.m755/rr-1Accessed 19 Apr 2020Google Scholar
  22. O. DyerCovid-19: black people and other minorities are hardest hit in USBMJ, 369 (2020), 10.1136/bmj.m1483Google Scholar
  23. A. Savarino, L.D. Trani, I. Donatelli, R. Cauda, A. CassoneNew insights into the antiviral effects of chloroquineLancet Infect Dis, 6 (2006), pp. 67-69ArticleDownload PDFView Record in ScopusGoogle Scholar
  24. G. Ruiz-Irastorza, N. Olivares, I. Ruiz-Arruza, A. Martinez-Berriotxoa, M.-V. Egurbide, C. AguirrePredictors of major infections in systemic lupus erythematosusArthritis Res Ther, 11 (2009), p. R109CrossRefView Record in ScopusGoogle Scholar
  25. E.J. Rubin, L.R. BadenMorrissey SAudio Interview: Loosening Covid-19 RestrictionsN Engl J Med, 382 (2020), p. e67CrossRefGoogle Scholar
  26. J.M. Sanders, M.L. Monogue, T.Z. Jodlowski, J.B. CutrellPharmacologic treatments for coronavirus disease 2019 (COVID-19): a reviewJAMA (2020), 10.1001/jama.2020.6019[Epub ahead of print]Google Scholar
  27. S.G. Deftereos, G. Siasos, G. Giannopoulos, D.A. Vrachatis, C. Angelidis, S.G. Giotaki, et al.The GReek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): rationale and study designHellenic J Cardiol (2020), 10.1016/j.hjc.2020.03.002Google Scholar
  28. D. Kanduc, Y. ShoenfeldOn the molecular determinants the SARS-CoV-2 attackClin Immunol (Orlando, Fla), 18 (2020), p. 215108426Google Scholar
  29. A. Kerpel, N. Nissan, M. Klug, S. Amit, E. Konen, E.M. MaromImaging findings in four COVID-19 patientsIMAJ, 22 (2020), pp. 214-215View Record in ScopusGoogle Scholar
  30. M. Infantino, A. Damiani, F.L. Gobbi, V. Grossi, B. Lari, D. Macchia, et al.Serological assays for SARS-CoV-2 infectious disease: benefits, limitations and perspectivesIMAJ, 22 (2020), pp. 203-210View Record in ScopusGoogle Scholar
  31. Y.Y. Leung, L.L.Y. Hui, V.B. KrausColchicine — update on mechanisms of action and therapeutic usesSemin Arthritis Rheum, 45 (2015), pp. 341-350ArticleDownload PDFView Record in ScopusGoogle Scholar
  32. Colchicine Counteracting Inflammation in COVID-19 Pneumonia – Full Text ViewClinicalTrials.gov (2020)https://clinicaltrials.gov/ct2/show/NCT04322565Accessed 21 Apr 2020Google Scholar
  33. Colchicine coronavirus SARS-CoV2 trial (COLCORONA) – full text view – ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04322682 (2020)Accessed 14 Apr 2020Google Scholar
  34. C. Tang, T. Godfrey, R. Stawell, M. NikpourHydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effectsIntern Med J, 42 (2012), pp. 968-978CrossRefView Record in ScopusGoogle Scholar
  35. T. Pascart, P. RichetteColchicine in gout: an updateCurr Pharm Des, 24 (2018), pp. 684-689View Record in ScopusGoogle Scholar
  36. C. Grossman, I. Farberov, O. Feld, A. Livneh, I. Ben-ZviEfficacy and safety of long-term treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicineRheumatol Int, 39 (2019), pp. 517-523CrossRefView Record in ScopusGoogle Scholar

感想

ヒドロクロロキンやコルヒチンについては、この試験を見る限りでは期待はできないのかもしれないなぁと思えます。とはいえ、継続的に後出の論文を見ていく必要がありそうです。

コメントを残す

このサイトはスパムを低減するために Akismet を使っています。コメントデータの処理方法の詳細はこちらをご覧ください